{
    "ticker": "BTTR",
    "name": "Better Therapeutics, Inc.",
    "description": "Better Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics for cardiometabolic diseases through the application of digital interventions. Founded in 2015, Better Therapeutics leverages a unique approach that combines behavior-based therapies with advanced software technology to treat conditions such as type 2 diabetes and obesity. The company's flagship product, BT-001, is a prescription digital therapeutic that aims to improve glycemic control and promote weight loss by engaging patients in cognitive behavioral therapy. Better Therapeutics is committed to delivering evidence-based solutions that empower patients to take charge of their health. By integrating behavioral science with digital health technologies, the company aims to enhance patient adherence and sustain long-term lifestyle changes. With a vision to revolutionize the treatment landscape for chronic diseases, Better Therapeutics is at the forefront of the digital health revolution, advocating for a holistic approach to patient care that addresses both psychological and physiological aspects of health.",
    "industry": [
        "Biotechnology",
        "Digital Health"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.bettertx.com",
    "ceo": "Kevin McEvenue",
    "social_media": {
        "twitter": "https://twitter.com/BetterThera",
        "linkedin": "https://www.linkedin.com/company/better-therapeutics/"
    },
    "investor_relations": "https://investors.bettertx.com",
    "key_executives": [
        {
            "name": "Kevin McEvenue",
            "position": "CEO"
        },
        {
            "name": "David M. H. Hwang",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Digital Therapeutics",
            "products": [
                "BT-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Better Therapeutics, Inc. | Digital Health Solutions for Chronic Diseases",
        "meta_description": "Explore Better Therapeutics, Inc., a leader in digital therapeutics for cardiometabolic diseases. Learn about our innovative products and commitment to patient health.",
        "keywords": [
            "Better Therapeutics",
            "Digital Health",
            "Cardiometabolic Diseases",
            "BT-001",
            "Type 2 Diabetes",
            "Obesity"
        ]
    },
    "faq": [
        {
            "question": "What does Better Therapeutics focus on?",
            "answer": "Better Therapeutics focuses on developing digital therapeutics for cardiometabolic diseases."
        },
        {
            "question": "Who is the CEO of Better Therapeutics?",
            "answer": "Kevin McEvenue is the CEO of Better Therapeutics, Inc."
        },
        {
            "question": "Where is Better Therapeutics headquartered?",
            "answer": "Better Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What is Better Therapeutics' main product?",
            "answer": "Better Therapeutics' main product is BT-001, a prescription digital therapeutic for type 2 diabetes."
        },
        {
            "question": "When was Better Therapeutics founded?",
            "answer": "Better Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "NVCR",
        "SLQT",
        "AMGN"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "GILD",
        "BMY"
    ]
}